Size: px
Start display at page:

Download ""

Transcription

1 , CASE REPORT ARIPIPRAZOLE IN PSYCHOTIC DEPRESSION: FOUR CASE REPORTS Kuppuswami Shivakumar, Amna Mir, Victoria D.M. McAllister, Veronica O Keane, Katherine J. Aitchison Summary Object: Aripiprazole is an antipsychotic with partial agonism activity at D 2 and 5-HT 1A receptors, not currently licensed for the treatment of psychotic depression (Burris et al and Jordan et al. 2002). This case series reports outcomes of using aripiprazole in the treatment of patients with psychotic depression. Methods: Four individuals with psychotic depression treated with a combination of an antidepressant and an antipsychotic with inadequate therapeutic response or intolerance were switched to aripiprazole. Clinical ratings included Positive and Negative Symptoms Scale (PANSS), Clinical Global Impression Scale for Severity/ Improvement (CGI-S/I), Global Assessment of Functioning Scale - Symptoms/ Disability (GAF-S/D), Antipsychotic Non- Neurological Side-Effects Rating Scale (ANNSERS, Yusufi et al. 2005), Quality of Life (QoL, Heinrichs et al. 1984) and Preference of Medication Scale (POM, a 1-5 scale, 1 = greatest preference). Results: Case 1: Switching was conducted without cross-tapering, and was uneventful. At one-year follow-up (on aripiprazole 10 mg and citalopram 40 mg), there was improvement on GAF-S (70 to 80), ANNSERS (16 to 5) and POM (1). Case 2: Cross-taper with amisulpride resulted in an improvement by 12 weeks in GAF-S (60 to 70), and ANNSERS (41 to 18). From week 26, depressive symptoms recurred. His medication (aripiprazole from 30 mg to 20 mg, citalopram 30 mg to 40 mg) was adjusted, which resulted in some improvement. However at one year, the patient was still reporting depressive symptoms along with paranoid ideation. At this point he was treated by introducing 200 mg of amisulpride. Case 3: Cross-taper with risperidone (4 mg) over 12 weeks was well tolerated and resulted by 1 year in a PANSS change from 71 to 40, CGI-S change from 3 to 1, and a POM score of 1. Case 4: Aripiprazole (10 mg to 15 mg over 2 weeks), cross-tapering with risperidone (2 mg), resulted in an improvement in his total side effects (ANNSERS from 13 to 9) as well as sexual side effects only by week 26. Conclusions: This case series suggests that further study of aripiprazole in the treatment of psychotic depression is indicated. Key words: Aripiprazole Psychosis Depression Dopamine Serotonin Agonist Declaration of interest: This study was funded by Bristol-Myers Squibb Pharmaceuticals Limited (see Acknowledgements). Dr Katherine J Aitchison is on the UK Core Steering Group for Abilify (Aripiprazole), and has received consultancy fees from Bristol-Myers Squibb Pharmaceuticals Limited. Kuppuswami Shivakumar, Amna Mir, Victoria D M McAllister, COAST Team (Croydon Early Onset Psychosis Service), Westways Resource Centre, 49 St James s Road, Croydon, UK Veronica O Keane, Perinatal Psychiatry Section of the Division of Psychological Medicine, King s College, London, UK Katherine J Aitchison, MRC Social, Genetic and Developmental Psychiatry Centre and Clinical Neuropharmacology Section of the Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, Internal Box PO 80, De Crespigny Park, London, SE5 8AF, UK Corresponding Author Katherine J Aitchison, MRC Social, Genetic and Developmental Psychiatry Centre and Clinical Neuropharmacology Section of the Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, Internal Box PO 80, De Crespigny Park, London, SE5 8AF, UK. Introduction There is mounting evidence to support the theory that depression with psychotic symptoms is not only the most difficult type of depression to treat, but is also associated with significantly greater morbidity and mortality than non-psychotic depression. The American Psychiatric Association guidelines recommend that major depression with psychotic features should be treated with an antipsychotic as well as an antidepressant (American Psychiatric Association 1993). Aripiprazole is a second generation antipsychotic that has partial agonism activity at D 2 and 5-HT 1A receptors. Clinical trials have demonstrated efficacy of RECEIVED MARCH 2006, ACCEPTED DECEMBER Giovanni Fioriti Editore s.r.l.

2 Aripiprazole in Psychotic Depression: Four Case Reports aripiprazole in the treatment of schizophrenia. However, aripiprazole does not currently hold a licence for the treatment of psychotic depression. Here we report four cases of psychotic depression treated with aripiprazole. Methods Subjects were recruited as a part of a study aiming to investigate changes in sexual dysfunction on switching to aripiprazole. They were recruited from the COAST Team (Croydon Early Intervention in Psychosis Service), and Croydon Community Mental Health Teams. The inclusion criteria were: subjects (male or female) in the age range 18 to 65 years, with a psychotic illness living in the community, who had failed to respond adequately to another antipsychotic (either inadequate therapeutic response or intolerance).there were no restrictions in terms of ethnicity. Open label switch to aripiprazole was offered to eligible subjects. The starting dose at the commencement of the study was 10 mg, but was reduced to 5 mg once the 5 mg tablets became available in the UK (January 2005). Clinical ratings performed included: Positive and Negative Syndrome Scale (PANSS: scale where 30 is absent), Clinical global impression scales (CGI-Severity of illness: 1 7 scale where 1 is normal; CGI- Improvement: 1-7 scale where 1 is very much improved), Global Assessment of Functioning Scale- Symptoms and Disability (GAF-S and GAF-D respectively: 1 90 scale where 1 is very low functioning), Antipsychotic Non-Neurological Side-Effects Rating Scale, (ANNSERS: scale where 0 is absence of any side effect; Yusufi et al. 2005), general satisfaction items regarding overall sexual functioning from the Sexual Functioning Questionnaire (SFQ: 0 10 scale where 10 is completely satisfied; Smith et al. 2002), and Quality of Life Scale (QoL: scale where 0 is poorest QoL; Heinrichs et al. 1984). Compliance was also measured (1 7 scale where 7 is very good compliance; Kemp et al. 1995) and a five point preference of medication questionnaire (PoM: 1-5 scale where 1 is the greatest preference, Tandon et al. 2006). Serial hormonal measurements including prolactin were also performed. The time points for all clinical ratings and serum levels were: baseline, and 1, 2, 6, 12, 26 and 52 weeks thereafter except for the Quality of Life Scale, which was applied only at baseline, week 26 and week 52. Case Series Case 1 Ms. W, a 37-year-old single mother, with a strong family history of psychiatric disorder first presented to psychiatric services in 2001 with a 2-week history of severe depressive symptoms with psychotic features. She was admitted, and a diagnosis of severe depressive symptoms with psychotic features was made. She was treated with olanzapine 12.5 mg/day and citalopram 10 mg/day, to which she showed some improvement. However, after 15 months of treatment, the reappearance of severe depressive symptoms with psychotic features and suicidal ideation led to an increase in the dose of olanzapine to 15 mg/day and citalopram to 40 mg/day. This produced a substantial increase in weight gain (13 kg in 6 months) with sexual dysfunction (decreased libido, galactorrhoea, and oligomenorrhoea) and increased prolactin level (4879 mu/l). Switching to amisulpride did not alleviate the side effects. Ms. W was switched to aripiprazole 10 mg/day in September 2004 and amisulpride was stopped without a cross-taper of the two medications (Figure 1). Her antidepressant dose (Citalopram 40 mg) remained the same. She reported some sleep difficulties in the first week and zopiclone 7.5 mg on an as required basis was prescribed for a week. By week 6, the side effects she was experiencing reduced from 16 to 4 on ANNSERS (total score), and the PANSS depression item score improved from 2 to 1. Her other psychopathology remained stable. Her preference of medication increased to much better (1). At one year follow-up, she remained well (Total PANSS = 32, PANSS depression item = 1, CGI-I = 1, GAF-D = 85) and the medication combination (aripiprazole 10 mg/day and citalopram 40 mg/day) was well tolerated (ANNSERS total score reduced from 16 to 5, with reduction in prolactin to 272 mu/l). Moreover, the sexual side effects that were reported at baseline had resolved. Her preference of medication was still much better as compared to her old antipsychotic and she was fully compliant (score on compliance measure = 7) with her treatment. Case 2 Mr. T, a 38-year-old married housing officer with a child is on long-term disability living allowance due to ill-health. He was diagnosed with recurrent depressive disorder with psychotic symptoms at 17 years, following a minor head injury. For the next 20 years, he remained severely depressed and socially impaired, despite different pharmacotherapeutic strategies. On referral to our team, he was on amisulpride 400 mg/day, citalopram 40 mg/day, lithium 1000 mg/day and reboxetine 8mg/day. Owing to ongoing depressive symptoms (PANSS depression item score = 3 (mild severity) with auditory hallucinations and sexual dysfunction, a switch to aripiprazole 10 mg/ day was initiated (Figure 2), gradually increasing to 30 mg/day over 14 weeks, with a cross-taper from amisulpride over 10 weeks. He remained on the same dose of lithium, reboxetine and citalopram. From 6 weeks after switching, he began to show improvement in his symptomatology. By week 12, the Positive and Negative Symptoms Scale (PANSS) score reduced from 43 to 35, with a 38.5% reduction in the negative subscale and the PANSS depression item reduced from 3 to 1, accompanied by an improvement in the CGI-I (3 to 1) and GAF-S (60 to 70). The adverse effects ratings also decreased over the 12-week period: ANNSERS (41 to 18), and Sexual Functioning Questionnaire (19 to 6). The patient reported some depressive symptoms at the 19-week review point (PANSS = 54, with score for depression item in PANSS = 6). His citalopram was increased from 20 mg to

3 Kuppuswami Shivakumar et al. $PLVXOSULGH Figure 1. Antipsychotics prescribed for Ms. W over period of observation $PLVXOSULGH &XUUHQW Figure 2. Antipsychotics prescribed for Mr. T over period of observation 334

4 Aripiprazole in Psychotic Depression: Four Case Reports 5LVSHULGRQH Figure 3. Antipsychotics prescribed for Mr. C over period of observation mg. This resulted in improvement of symptoms within a week (PANSS = 33). This improvement was maintained at 26-week follow up (PANSS = 36, GAF- S = 70, GAF-D = 75, CGI-I = 1, PoM = 1, ANNSERS = 17). Mr. T also reported significant improvement in social functioning, reflected in the Quality of Life rating (18 to 87 at 26 weeks). After 7 months of being on aripiprazole, he started to report some deterioration in his mood with reoccurrence of some psychotic symptoms. Within a month, his mood and psychotic symptoms had worsened. At that time Mr. T was having some relationship difficulties with his wife. His daughter also had some symptoms of low mood symptoms similar to Mr T which was of concern to him. He was also stressed about starting of a new voluntary job. This contributed to the exacerbation of the symptoms. His antidepressant was increased (from 30 mg/day of citalopram to 40 mg/ day), which resulted in some improvement, but he still had some depressive symptoms and paranoid ideation. Simultaneously, his aripiprazole was reduced to 20 mg/ day, as it was thought that the aripiprazole might have been contributing to an exacerbation of his psychotic symptoms. At one year follow up, no improvement in his symptoms was noted (PANSS = 66, PANSS depression item = 5, GAF-D = 51). As a result, amisulpride 200 mg/day was added to his treatment regime (Aripiprazole 20 mg, citalopram 40 mg, reboxetine 8 mg, lithium 1000 mg). This resulted in improvement of both his depressive and psychotic symptoms. Case 3 Mr. C, a 27-year-old single chef, unemployed since the onset of his illness, with no family history of psychiatric illness, had a 12-month history of progressively worsening severe depressive symptoms with delusions. He was initially treated with risperidone 4 mg and citalopram 40 mg, to which he responded poorly (PANSS score of 71, predominantly negative symptoms; PANSS depression item = 3). He also had side effects, including prolactin elevation (1244 mu/l), weight gain and sexual side effects. He was started on aripiprazole 10 mg/day, with a gradual cross-taper of risperidone over 12 weeks, increasing to 20 mg/day of aripiprazole after week 12. His antidepressant dose remained the same. At one year, he remained on aripiprazole 20 mg/day (Figure 3) and citalopram 40 mg/day, and this regime was clinically well tolerated. He remains well with reduction in total PANSS score to 40 and PANSS depression item score to 1 (absent) after 1 year, with an improvement also on other measures by one year follow up: CGI-S (3 to 1), CGI-I (1), GAF-D (41 to 80), QoL (69 to 86), ANNSERS (from 21 to 4), Compliance (7) and POM (1). 335

5 Kuppuswami Shivakumar et al. 5LVSHULGRQH &XUUHQW Figure 4. Antipsychotics prescribed for Mr. P over period of observation Case 4 Mr. P, a 27-year-old male with a history of severe depressive symptoms with psychotic features, presented with low mood, suicidal ideation and psychotic symptoms characterised by thought disorder, auditory hallucinations and delusions in August He was initially treated with fluoxetine and then also with olanzapine, to which he responded poorly. The olanzapine was switched to risperidone 3 mg, and symptoms were controlled. However, three months later, he developed extra pyramidal side effects (tremor), and the risperidone was reduced to 2 mg. In early 2004, he developed severe sexual side effects (delayed erection, retrograde ejaculation and loss of libido) and weight gain. He was on risperidone 2 mg and clonazepam 1 mg at that time. Aripiprazole 10 mg was commenced in July 2004, increasing up to 15 mg over 2 weeks, cross-tapering with the risperidone. His clonazepam was stopped after 2 weeks of being on aripiprazole. This resulted in an improvement in his side effects and psychopathology by week 26. The total side effect score on the ANNSERS reduced from 13 to 9 by one year, including improvement in all four measures of sexual dysfunction on this scale. His psychopathology remained stable (PANSS = 33, PANSS depression item = 1, GAF-D = 75) after two years and four months on aripiprazole 15 mg in this case (Figure 4). He was fully compliant with the medication (7) and preferred this medication regime much better on preference of medication scale (1). Interestingly, this has been achieved as monotherapy, in the absence of an antidepressant. Discussion Our data suggest that aripiprazole has efficacy either alone or in combination treatment in psychotic depression. Three out of four cases of psychotic depression found aripiprazole to be effective in reducing both their psychotic and depressive symptoms. Moreover, they experienced less adverse effects than on their previous treatment regime. However, one patient relapsed after 7 months of being on aripiprazole. Of note, the maximum dose of aripiprazole used in this case (30 mg) was higher than that in the other cases. It is possible that his remaining on 30 mg for a total of 5 months contributed to the destabilisation at month 7, and that had his aripiprazole been reduced to 15 mg at week 26, that this could have been avoided. However, this case also had the longest duration of illness, and a history of a head injury and psychosocial stressors, all of which could have contributed to increased likelihood of relapse. The partial agonism of aripiprazole at both serotonin 5HT 1A and dopamine D 2 receptors is consistent with our findings. Further studies and clinical 336

6 Aripiprazole in Psychotic Depression: Four Case Reports trials of aripiprazole in the treatment of psychotic depression are indicated. Acknowledgements This study was funded by Bristol-Myers Squibb Pharmaceuticals Limited (Investigator Sponsored Study, Principal Investigator: Dr KJ Aitchison). However, none of the grant was used for antipsychotic prescriptions. We thank Dr Holloway (Clinical Director, Croydon Integrated Adult Mental Health Services), and the COAST and local Community Mental Health team staff and service users for their assistance with and participation in this study. References Heinrich DN, Hanton TE, Carpenter WT (1984). The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bulletin 10, American Psychiatric Association (1993). Practice guideline for major depressive disorder in adults. Am J Psychiatry 150, Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002). Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors. Psychopharmacol 302, Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002). The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT 1A receptor. Eur J Psychopharmacol 441, Kemp R, Hayward P, Applewhaite G, Everitt B, David A (1995). Compliance therapy on psychotic patients: randomized controlled trial. BMJ 312, Smith S, O Keane V, Murray R (2002). Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 181, Tandon R, Marcus R N, Stock E G, Riera L C, Kostic D, Pans M, McQuade R D, Nyilas M, Iwamoto T, Crandall D T (2006). A prospective, multicentre, randomized, parallelgroup, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad effectiveness trial with aripiprazole (BETA). Schiz Res 84, 1, Yusufi BZ, Mukherjee S, Aitchison K, Dunn G, Page E, Barnes TRE (2005). Reliability of the Antipsychotic Non- Neurological Side-Effects Rating Scale (ANNSERS). J Psychopharmacol 19 suppl, A

placebo-controlledcontrolled double-blind, blind,

placebo-controlledcontrolled double-blind, blind, Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which

More information

Conjoint Professor Brian Draper

Conjoint Professor Brian Draper Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course

More information

Update on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice

Update on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological

More information

Antipsychotic drugs are the cornerstone of treatment

Antipsychotic drugs are the cornerstone of treatment Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,

More information

PSYCHIATRY FOR PCPs BIPOLAR DISORDER

PSYCHIATRY FOR PCPs BIPOLAR DISORDER PSYCHIATRY FOR PCPs BIPOLAR DISORDER David A Harrison, MD, PhD Assistant Professor Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Mood Disorders: Diagnosis & Treatment

More information

MANAGING PATIENTS WITH CHRONIC MENTAL HEALTH PROBLEMS IN PRIMARY CARE

MANAGING PATIENTS WITH CHRONIC MENTAL HEALTH PROBLEMS IN PRIMARY CARE MANAGING PATIENTS WITH CHRONIC MENTAL HEALTH PROBLEMS IN PRIMARY CARE Dr Ilyas Mirza Psychiatric Consultant Barnet Enfield & Haringey Mental Health Trust CHRONIC MENTAL HEALTH Anxiety disorders PROBLEMS

More information

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,

More information

Depression Flow Chart

Depression Flow Chart Depression Flow Chart SCREEN FOR DEPRESSION ANNUALLY Assess for depression annually with the PHQ-9. Maintain a high index of suspicion in high risk older adults. Consider suicide risk and contributing

More information

Bipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:

Bipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include: Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic

More information

SYNOPSIS. Risperidone: Clinical Study Report CR003274

SYNOPSIS. Risperidone: Clinical Study Report CR003274 SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:

More information

This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.

This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge

More information

Algorithm for Initiating Antidepressant Therapy in Depression

Algorithm for Initiating Antidepressant Therapy in Depression Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression

More information

TREATING MAJOR DEPRESSIVE DISORDER

TREATING MAJOR DEPRESSIVE DISORDER TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.

More information

These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.

These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical

More information

Serious Mental Illness: Symptoms, Treatment and Causes of Relapse

Serious Mental Illness: Symptoms, Treatment and Causes of Relapse Serious Mental Illness: Symptoms, Treatment and Causes of Relapse Bipolar Disorder, Schizophrenia and Schizoaffective Disorder Symptoms and Prevalence of Bipolar Disorder Bipolar disorder, formerly known

More information

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour. Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,

More information

DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource

DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population

More information

MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION

MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Clinical evaluation D The basic

More information

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,

More information

Family Guide To Understanding Antipsychotic Medications Prescribed For Persons With Mental Retardation and Developmental Disabilities

Family Guide To Understanding Antipsychotic Medications Prescribed For Persons With Mental Retardation and Developmental Disabilities Family Guide To Understanding Antipsychotic Medications Prescribed For Persons With Mental Retardation and Developmental Disabilities What are Psychotic Symptoms? Antipsychotic medications are powerful,

More information

TREATMENT-RESISTANT DEPRESSION AND ANXIETY

TREATMENT-RESISTANT DEPRESSION AND ANXIETY University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2

More information

Comorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014

Comorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014 Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment

More information

Emergency Room Treatment of Psychosis

Emergency Room Treatment of Psychosis OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different

More information

Psychosis Psychosis-substance use Bipolar Affective Disorder Programmes EASY JCEP EPISO Prodrome

Psychosis Psychosis-substance use Bipolar Affective Disorder Programmes EASY JCEP EPISO Prodrome Dr. May Lam Assistant Professor, Department of Psychiatry, The University of Hong Kong Psychosis Psychosis-substance use Bipolar Affective Disorder Programmes EASY JCEP EPISO Prodrome a mental state in

More information

Overview of Mental Health Medication Trends

Overview of Mental Health Medication Trends America s State of Mind Report is a Medco Health Solutions, Inc. analysis examining trends in the utilization of mental health related medications among the insured population. The research reviewed prescription

More information

Corporate Presentation May 13, 2015

Corporate Presentation May 13, 2015 Corporate Presentation May 13, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events and

More information

Management of Bipolar Disorder in Adults

Management of Bipolar Disorder in Adults QUICK REFERENCE F HEALTHCARE PROVIDERS Management of Bipolar Disorder in Adults Ministry of Health Malaysia Malaysian Psychiatric Association Academy of Medicine Malaysia KEY MESSAGES 1. Management of

More information

1. Which of the following SSRIs requires up to a 5-week washout period because of the

1. Which of the following SSRIs requires up to a 5-week washout period because of the 1 Chapter 38. Major Depressive Disorders, Self-Assessment Questions 1. Which of the following SSRIs requires up to a 5-week washout period because of the long half-life of its potent active metabolite?

More information

Dementa Formulary Guidance [v1.0]

Dementa Formulary Guidance [v1.0] Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more

More information

Prescribing antipsychotics to older people: report from pilot study

Prescribing antipsychotics to older people: report from pilot study Prescribing antipsychotics to older people: report from pilot study Prepared by Rebecca Harris, bpac nz for PHARMAC September, 2015 bpac nz Prescribing antipsychotics to older people: Report from pilot

More information

DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE

DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE 1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff

More information

Psychopharmacotherapy for Children and Adolescents

Psychopharmacotherapy for Children and Adolescents TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners

More information

Diagnosis and Treatment of Bipolar Disorder. Marissa Mariano-Mejia, M.D. Adult Psychiatrist July 2, 2016

Diagnosis and Treatment of Bipolar Disorder. Marissa Mariano-Mejia, M.D. Adult Psychiatrist July 2, 2016 Diagnosis and Treatment of Bipolar Disorder Marissa Mariano-Mejia, M.D. Adult Psychiatrist July 2, 2016 Points to Cover What is the defining characteristic of Bipolar Disorder? Bipolar I vs. Bipolar II

More information

Depre r s e sio i n o i n i a dults Yousuf Al Farsi

Depre r s e sio i n o i n i a dults Yousuf Al Farsi Depression in adults Yousuf Al Farsi Objectives 1. Aetiology 2. Classification 3. Major depression 4. Screening 5. Differential diagnosis 6. Treatment approach 7. When to refer 8. Complication 9. Prognosis

More information

(4) To characterize the course of illness after adequate response to and continuation on the treatments found effective for individual participants.

(4) To characterize the course of illness after adequate response to and continuation on the treatments found effective for individual participants. I. Specific Aims/Objectives STAR*D has several main objectives and is powered to assess the effectiveness of a sequence of treatments at various levels of treatment. Most of these objectives entail evaluating

More information

in young people Management of depression in primary care Key recommendations: 1 Management

in young people Management of depression in primary care Key recommendations: 1 Management Management of depression in young people in primary care Key recommendations: 1 Management A young person with mild or moderate depression should typically be managed within primary care services A strength-based

More information

NICE Clinical guideline 23

NICE Clinical guideline 23 NICE Clinical guideline 23 Depression Management of depression in primary and secondary care Consultation on amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised

More information

THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine

THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine Volume 1, Issue 1 August 2007 The Depression Research Clinic at Stanford University

More information

Costing statement: Depression: the treatment and management of depression in adults. (update) and

Costing statement: Depression: the treatment and management of depression in adults. (update) and Costing statement: Depression: the treatment and management of depression in adults (update) and Depression in adults with a chronic physical health problem: treatment and management Summary It has not

More information

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations

More information

MAJOR DEPRESSION DURING CONCEPTION AND PREGNANCY: A Guide for Patients and Families

MAJOR DEPRESSION DURING CONCEPTION AND PREGNANCY: A Guide for Patients and Families MAJOR DEPRESSION DURING CONCEPTION AND PREGNANCY: A Guide for Patients and Families David A. Kahn, MD, Margaret L. Moline, PhD, Ruth W. Ross, MA, Lee S. Cohen, MD, and Lori L. Altshuler, MD www.womensmentalhealth.org

More information

Psychosocial Risk Factors. Women s Mental Health. Prevalence of Mood Disorders by Gender. Depression in Women: Contributing Factors

Psychosocial Risk Factors. Women s Mental Health. Prevalence of Mood Disorders by Gender. Depression in Women: Contributing Factors Women s Mental Health Linda S. Mullen, MD Director, Women s Mental Health Assistant Professor of Clinical Psychiatry in OB/GYN Columbia University & NewYork Presbyterian Hospital Departments of Psychiatry

More information

Depression in Older Persons

Depression in Older Persons Depression in Older Persons How common is depression in later life? Depression affects more than 6.5 million of the 35 million Americans aged 65 or older. Most people in this stage of life with depression

More information

PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health

PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that

More information

making sense of psychiatric medication making sense psychiatric medication

making sense of psychiatric medication making sense psychiatric medication making sense of psychiatric medication making sense psychiatric medication Making sense of psychiatric medication This booklet is for anyone who wants to know more about psychiatric medication. It explains

More information

IMR ISSUES, DECISIONS AND RATIONALES The Final Determination was based on decisions for the disputed items/services set forth below:

IMR ISSUES, DECISIONS AND RATIONALES The Final Determination was based on decisions for the disputed items/services set forth below: Case Number: CM13-0018009 Date Assigned: 10/11/2013 Date of Injury: 06/11/2004 Decision Date: 01/13/2014 UR Denial Date: 08/16/2013 Priority: Standard Application Received: 08/29/2013 HOW THE IMR FINAL

More information

Depression & Multiple Sclerosis

Depression & Multiple Sclerosis Depression & Multiple Sclerosis Managing specific issues Aaron, diagnosed in 1995. The words depressed and depression are used so casually in everyday conversation that their meaning has become murky.

More information

BRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS

BRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS BRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems

More information

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität

More information

Much of our current conceptual

Much of our current conceptual DIAGNOSTIC BOUNDARIES BETWEEN BIPOLAR DISORDER AND SCHIZOPHRENIA: IMPLICATIONS FOR PHARMACOLOGIC INTERVENTION * Stephen M. Strakowski, MD ABSTRACT Schizophrenia and bipolar disorder are distinguished primarily

More information

D. Clinical indicators for psychiatric evaluation are established by one or more of the following criteria. The consumer is:

D. Clinical indicators for psychiatric evaluation are established by one or more of the following criteria. The consumer is: MCCMH MCO Policy 2-015 Date: 4/21/11 V. Standards A. A psychiatric evaluation shall be done as an integral part of the assessment process. It serves as the guide to the identification of medical and psychiatric

More information

POSTPARTUM DEPRESSION: A Guide for Patients and Families

POSTPARTUM DEPRESSION: A Guide for Patients and Families POSTPARTUM DEPRESSION: A Guide for Patients and Families Margaret L. Moline, PhD, David A. Kahn, MD, Ruth W. Ross, MA, Lori L. Altshuler, MD, and Lee S. Cohen, MD www.womensmentalhealth.org The birth of

More information

Amendments to recommendations concerning venlafaxine

Amendments to recommendations concerning venlafaxine Amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised prescribing advice for venlafaxine*. This amendment brings the guideline into line with the new advice but does

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update) 1.1

More information

Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller

Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller School of Medicine/University of Miami Question 1 You

More information

Management of depression in young people

Management of depression in young people Management of depression in young people A guide for primary care health professionals For young people not in immediate danger of suicidal behaviour, management of major depressive disorder is likely

More information

Psychotherapeutic Medication: Treatment Resistant Depression

Psychotherapeutic Medication: Treatment Resistant Depression Pacific University CommonKnowledge Faculty Scholarship (PHRM) School of Pharmacy 2010 Psychotherapeutic Medication: Treatment Resistant Depression David Fuentes Pacific University Follow this and additional

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of

More information

Emotional dysfunction in psychosis.

Emotional dysfunction in psychosis. Early intervention Service Emotional dysfunction in psychosis. 2. Depression In First Episode Psychosis (DIPS) study: The role of awareness and appraisal Max Birchwood and Rachel Upthegrove Background:

More information

[KQ 804] FEBRUARY 2007 Sub. Code: 9105

[KQ 804] FEBRUARY 2007 Sub. Code: 9105 [KQ 804] FEBRUARY 2007 Sub. Code: 9105 (Revised Regulations) Theory : Two hours and forty minutes Q.P. Code: 419105 Maximum : 100 marks Theory : 80 marks M.C.Q. : Twenty minutes M.C.Q. : 20 marks 1. A

More information

Abnormal Psychology PSY-350-TE

Abnormal Psychology PSY-350-TE Abnormal Psychology PSY-350-TE This TECEP tests the material usually taught in a one-semester course in abnormal psychology. It focuses on the causes of abnormality, the different forms of abnormal behavior,

More information

NICE clinical guideline 90

NICE clinical guideline 90 Depression in adults The treatment and management of depression in adults Issued: October 2009 NICE clinical guideline 90 guidance.nice.org.uk/cg90 NHS Evidence has accredited the process used by the Centre

More information

Mohammad Amjad ullah Khan, M.D. Child, Adolescent and Adult Psychiatry Texas A & M University Scott & White Healthcare System Temple and Killeen

Mohammad Amjad ullah Khan, M.D. Child, Adolescent and Adult Psychiatry Texas A & M University Scott & White Healthcare System Temple and Killeen Mohammad Amjad ullah Khan, M.D. Child, Adolescent and Adult Psychiatry Texas A & M University Scott & White Healthcare System Temple and Killeen Sadness of mood for most of the day, nearly every day, and/or

More information

Depression: Facility Assessment Checklists

Depression: Facility Assessment Checklists Depression: Facility Assessment Checklists A facility system assessment is a starting point for a quality improvement project. The checklists included in this booklet will be most useful if you take a

More information

Published 09 September 2013 1. 09 August 2013

Published 09 September 2013 1. 09 August 2013 aripiprazole 5mg, 10mg, 15mg, 30mg tablets, 10mg, 15mg orodispersible tablets, 1mg/mL oral solution (Abilify ) SMC No. (891/13) Otsuka Pharmaceutical (UK) Ltd 09 August 2013 The Scottish Medicines Consortium

More information

Billing for other services for members in psychiatric residential treatment facilities

Billing for other services for members in psychiatric residential treatment facilities Billing for other services for members in psychiatric residential treatment facilities Summary: Psychiatric residential treatment facilities (PRTF) are an all-inclusive treatment program for children and

More information

Trends in Prescribing of Antipsychotic Drugs in General Practice in England (Chart 1) 2.0. Other second generation antipsychotics (SGA)

Trends in Prescribing of Antipsychotic Drugs in General Practice in England (Chart 1) 2.0. Other second generation antipsychotics (SGA) Antipsychotic drugs Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as typical antipsychotics) and second generation antipsychotics (SGAs, formerly known

More information

Guidelines for the Treatment of

Guidelines for the Treatment of Guidelines for the Treatment of Adult ADHD with Psychostimulants Introduction This guideline covers the diagnosis and management of attention deficit hyperactivity disorder (ADHD) in adults (>18 years

More information

Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers

Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers SUPPLEMENT 1: (Supplementary Material for online publication) Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers About this

More information

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015 The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least

More information

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,

More information

Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)

Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures

More information

Bipolar Disorder: Advances in Psychotherapy

Bipolar Disorder: Advances in Psychotherapy Bipolar Disorder: Advances in Psychotherapy Questions from chapter 1 1) Which is characterized by one or more major depressive episodes with at least one hypomanic episode in which the patient s functioning

More information

New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine

New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept

More information

Applying ACT to Cases of Complex Depression: New Clinical and Research Perspectives

Applying ACT to Cases of Complex Depression: New Clinical and Research Perspectives Applying ACT to Cases of Complex Depression: New Clinical and Research Perspectives Part I: Depression with Psychosis and Suicidality Brandon Gaudiano, Ph.D. Assistant Professor of Psychiatry Grant Support:

More information

I. The Positive Symptoms...Page 2. The Negative Symptoms...Page 2. Primary Psychiatric Conditions...Page 2

I. The Positive Symptoms...Page 2. The Negative Symptoms...Page 2. Primary Psychiatric Conditions...Page 2 SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Assessment & Treatment of Psychosis Developed March 1, 2003 Revised September 21,

More information

Initial Evaluation for Post-Traumatic Stress Disorder Examination

Initial Evaluation for Post-Traumatic Stress Disorder Examination Initial Evaluation for Post-Traumatic Stress Disorder Examination Name: Date of Exam: SSN: C-number: Place of Exam: The following health care providers can perform initial examinations for PTSD. a board-certified

More information

Psychiatric Disorders

Psychiatric Disorders Psychiatric Disorders Learning about the brain from diagnosis to treatment Tedi Asher Harvard Medical School Talk overview Part I: Defining psychiatric disorders Part II: Biological underpinnings of depression

More information

Drugs PSYCHOSIS. Depression. Stress Medical Illness. Mania. Schizophrenia

Drugs PSYCHOSIS. Depression. Stress Medical Illness. Mania. Schizophrenia Drugs Stress Medical Illness PSYCHOSIS Depression Schizophrenia Mania Disorders In preschool children imaginary friends and belief in monsters under the bed is normal (it may be normal in older developmentally

More information

Improving the Recognition and Treatment of Bipolar Depression

Improving the Recognition and Treatment of Bipolar Depression Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating

More information

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT

More information

Best Practices Treatment Guideline for Major Depression

Best Practices Treatment Guideline for Major Depression Best Practices Treatment Guideline for Major Depression Special Report on New Depression Treatment Technology Based on 2010 APA Practice Guidelines Best Practices Guideline for the Treatment of Patients

More information

A Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.

A Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood. Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)

More information

Recognizing and Treating Depression in Children and Adolescents.

Recognizing and Treating Depression in Children and Adolescents. Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital

More information

Long Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)

Long Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine) 1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s

More information

Psychiatric Comorbidity in Methamphetamine-Dependent Patients

Psychiatric Comorbidity in Methamphetamine-Dependent Patients Psychiatric Comorbidity in Methamphetamine-Dependent Patients Suzette Glasner-Edwards, Ph.D. UCLA Integrated Substance Abuse Programs August11 th, 2010 Overview Comorbidity in substance users Risk factors

More information

Psychotic Disorder. Psychosis. Psychoses may be caused by: Examples of Hallucinations and Delusions 12/12/2012

Psychotic Disorder. Psychosis. Psychoses may be caused by: Examples of Hallucinations and Delusions 12/12/2012 Psychosis Psychotic Disorder Dr Lim Boon Leng Psychiatrist and Medical Director Dr BL Lim Centre For Psychological Wellness Tel: 64796456 Email: info@psywellness.com.sg Web: www.psywellness.com.sg A condition

More information

309.28 F43.22 Adjustment disorder with mixed anxiety and depressed mood Adjustment disorder with disturbance of conduct

309.28 F43.22 Adjustment disorder with mixed anxiety and depressed mood Adjustment disorder with disturbance of conduct Description ICD-9-CM Code ICD-10-CM Code Adjustment reaction with adjustment disorder with depressed mood 309.0 F43.21 Adjustment disorder with depressed mood Adjustment disorder with anxiety 309.24 F43.22

More information

Psychiatric Adverse Drug Reactions: Steroid Psychosis

Psychiatric Adverse Drug Reactions: Steroid Psychosis Psychiatric Adverse Drug Reactions: Steroid Psychosis Richard C.W. Hall, M.D. Medical Director, Psychiatric Programs Clinical Professor of Psychiatry University of Florida, Gainesville Director of Research

More information

Symptoms of mania can include: 3

Symptoms of mania can include: 3 Bipolar Disorder This factsheet gives information on bipolar disorder. It explains the symptoms of bipolar disorder, treatments and ways to manage symptoms. It also covers what treatment the National Institute

More information

Schizoaffective disorder

Schizoaffective disorder Schizoaffective disorder Dr.Varunee Mekareeya,M.D.,FRCPsychT Schizoaffective disorder is a psychiatric disorder that affects about 0.5 to 0.8 percent of the population. It is characterized by disordered

More information

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further

More information

Music therapy as a treatment for schizophrenia

Music therapy as a treatment for schizophrenia Music therapy as a treatment for schizophrenia George Sismey George Gillett University of Oxford October 2015 The question Scenario: 42 year old man with schizophrenia has read a newspaper article suggesting

More information

Major Depressive Disorder (MDD) Guideline Diagnostic Nomenclature for Clinical Depressive Conditions

Major Depressive Disorder (MDD) Guideline Diagnostic Nomenclature for Clinical Depressive Conditions Major Depressive Disorder Major Depressive Disorder (MDD) Guideline Diagnostic omenclature for Clinical Depressive Conditions Conditions Diagnostic Criteria Duration Major Depression 5 of the following

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. Using antidepressants in children and young people bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They

More information

MOLINA HEALTHCARE OF CALIFORNIA

MOLINA HEALTHCARE OF CALIFORNIA MOLINA HEALTHCARE OF CALIFORNIA MAJOR DEPRESSION IN ADULTS IN PRIMARY CARE HEALTH CARE GUIDELINE (ICSI) Health Care Guideline Twelfth Edition May 2009. The guideline was reviewed and adopted by the Molina

More information

Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease

Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Professional Tool #1: Screening and Monitoring in a High-Risk Population: Questions and Answers Overview of Cardiometabolic

More information

Clinical Audit: Prescribing antipsychotic medication for people with dementia

Clinical Audit: Prescribing antipsychotic medication for people with dementia Clinical Audit: Prescribing antipsychotic medication for people with dementia Trust, team and patient information Q1. Patient's DIS number... Q2. Patient s residence: Home Residential Home Nursing Home

More information

Magistrates Court Diversion Program. Sue King Manager, Intervention Programs April 2011

Magistrates Court Diversion Program. Sue King Manager, Intervention Programs April 2011 Magistrates Court Diversion Program Sue King Manager, Intervention Programs April 2011 Program Aims 1) Provide assistance to the court in the identification and management of defendants with mental impairment.

More information

Medication Management of Depressive Disorders in Children and Adolescents. Satya Tata, M.D. Kansas University Medical Center

Medication Management of Depressive Disorders in Children and Adolescents. Satya Tata, M.D. Kansas University Medical Center Medication Management of Depressive Disorders in Children and Adolescents Satya Tata, M.D. Kansas University Medical Center First Line Medications SSRIs Prozac (Fluoxetine): 5-605 mg Zoloft (Sertraline):

More information